Jazz Pharmaceuticals
JAZZ
461 hedge funds and large institutions have $8.82B invested in Jazz Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 151 increasing their positions, 146 reducing their positions, and 59 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
27% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 59
23% more call options, than puts
Call options by funds: $58.7M | Put options by funds: $47.8M
21% more capital invested
Capital invested by funds: $7.29B → $8.82B (+$1.53B)
2% more funds holding
Funds holding: 454 → 461 (+7)
3% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 146
1.87% less ownership
Funds ownership: 94.02% → 92.15% (-1.9%)
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$74.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$64.4M |
| 3 |
Millennium Management
New York
|
+$53.2M |
| 4 |
SC
Samlyn Capital
New York
|
+$41.2M |
| 5 |
ACM
Atika Capital Management
New York
|
+$28.9M |
Top Sellers
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$75.7M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$71.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$70.8M |
| 4 |
AC
Armistice Capital
New York
|
-$58.9M |
| 5 |
HM
HealthCor Management
New York
|
-$49.3M |
JAZZ Hedge Fund Activity: Q1 2022 in Review
461 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2022, worth a combined $8.82B — up 21% from $7.29B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new JAZZ positions and 59 closed out — a net gain of 16 holders — while 151 added to existing stakes and 146 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $74.9M. The largest seller was Boston Partners, cutting an estimated $75.7M.
- 461 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2022, up from 454 in Q4 2021.
- Funds reported $8.82B of Jazz Pharmaceuticals stock for Q1 2022, up 21% quarter-over-quarter.
- 75 funds opened new Jazz Pharmaceuticals positions in Q1 2022 and 59 closed out, a net change of +16 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2022 was PFM Health Sciences, an estimated $74.9M added.
- The largest Jazz Pharmaceuticals seller in Q1 2022 was Boston Partners, an estimated $75.7M sold.
Based on aggregated 13F filings for Q1 2022.